I am disappointed with the report.
Fourth Quarter 2021 Financial Highlights:
- Net revenues were $60.9 million compared to $57.3 million in Q4 2020.
- GAAP net loss was $24.1 million, and diluted GAAP loss per share was $1.72.
- Adjusted non-GAAP EBITDA was $16.2 million compared to $17.2 million in Q4 2020.
- Adjusted non-GAAP diluted earnings per share was $0.54, compared to $0.80 in Q4 2020.
- Cash and cash equivalents were $100.3 million, net accounts receivable was $128.5 million, and face value of debt was $300.0 million as of December 31, 2021.
Full Year 2021 Financial Highlights:
- Net revenues for 2021 were $216.1 million compared to $208.5 million in 2020.
- GAAP net loss was $42.6 million, and diluted GAAP loss per share was $3.40.
- Adjusted non-GAAP EBITDA was $64.8 million.
- Adjusted non-GAAP diluted earnings per share was $3.21.
[Source: BioSpace]
Anyone else expected better results?